Wow. That was remarkably polite given how unprofessional the original report was.

For those of you who are skimming this thread, read the response and skip the article. The GAO's report is premature on anything substantial, except (possibly) these companies should emphasize that some of their secondary "conclusions" are quite tentative.

The response points out that there are good conclusions from these companies with which the GAO does not find exception.

Key quote from response about function the GAO didn't disparage: [We] provide information about carrier status for single gene diseases such as cystic fibrosis and Tay-Sachs disease, as well as the fact that we provide information about a customer’s likely response to certain prescription medications that have been shown in clinical trials to have differing effects and side effects depending on a person’s genetic make-up